Logo image of ANVS

ANNOVIS BIO (ANVS) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:ANVS - US03615A1088 - Common Stock

4.5893 USD
+0.29 (+6.73%)
Last: 12/9/2025, 10:16:03 AM
Fundamental Rating

2

ANVS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. The financial health of ANVS is average, but there are quite some concerns on its profitability. ANVS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ANVS had negative earnings in the past year.
In the past year ANVS has reported a negative cash flow from operations.
ANVS had negative earnings in each of the past 5 years.
ANVS had a negative operating cash flow in each of the past 5 years.
ANVS Yearly Net Income VS EBIT VS OCF VS FCFANVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

ANVS has a worse Return On Assets (-144.77%) than 84.93% of its industry peers.
ANVS's Return On Equity of -189.15% is on the low side compared to the rest of the industry. ANVS is outperformed by 68.17% of its industry peers.
Industry RankSector Rank
ROA -144.77%
ROE -189.15%
ROIC N/A
ROA(3y)-265.83%
ROA(5y)-179.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANVS Yearly ROA, ROE, ROICANVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANVS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANVS Yearly Profit, Operating, Gross MarginsANVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, ANVS has more shares outstanding
The number of shares outstanding for ANVS has been increased compared to 5 years ago.
There is no outstanding debt for ANVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANVS Yearly Shares OutstandingANVS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
ANVS Yearly Total Debt VS Total AssetsANVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

ANVS has an Altman-Z score of 0.23. This is a bad value and indicates that ANVS is not financially healthy and even has some risk of bankruptcy.
ANVS has a Altman-Z score of 0.23. This is comparable to the rest of the industry: ANVS outperforms 59.32% of its industry peers.
ANVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.23
ROIC/WACCN/A
WACCN/A
ANVS Yearly LT Debt VS Equity VS FCFANVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 4.60 indicates that ANVS has no problem at all paying its short term obligations.
The Current ratio of ANVS (4.60) is comparable to the rest of the industry.
ANVS has a Quick Ratio of 4.60. This indicates that ANVS is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.60, ANVS perfoms like the industry average, outperforming 53.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.6
Quick Ratio 4.6
ANVS Yearly Current Assets VS Current LiabilitesANVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

ANVS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.33%, which is quite impressive.
EPS 1Y (TTM)60.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ANVS will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.24% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y24.9%
EPS Next 2Y10.31%
EPS Next 3Y9.12%
EPS Next 5Y12.24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANVS Yearly Revenue VS EstimatesANVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M
ANVS Yearly EPS VS EstimatesANVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ANVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANVS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANVS Price Earnings VS Forward Price EarningsANVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANVS Per share dataANVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.31%
EPS Next 3Y9.12%

More info and screens

0

5. Dividend

5.1 Amount

ANVS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANNOVIS BIO

NYSE:ANVS (12/9/2025, 10:16:03 AM)

4.5893

+0.29 (+6.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-19 2026-03-19/bmo
Inst Owners11.35%
Inst Owner Change10.04%
Ins Owners15.39%
Ins Owner Change4.4%
Market Cap121.62M
Revenue(TTM)N/A
Net Income(TTM)-24.88M
Analysts82
Price Target14.03 (205.71%)
Short Float %5.84%
Short Ratio0.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.56%
Min EPS beat(2)-18.93%
Max EPS beat(2)22.06%
EPS beat(4)2
Avg EPS beat(4)-3.11%
Min EPS beat(4)-27.55%
Max EPS beat(4)22.06%
EPS beat(8)4
Avg EPS beat(8)-2.96%
EPS beat(12)6
Avg EPS beat(12)-20.57%
EPS beat(16)7
Avg EPS beat(16)-32.21%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.51%
EPS NQ rev (1m)-10.75%
EPS NQ rev (3m)-13.5%
EPS NY rev (1m)-6.52%
EPS NY rev (3m)1.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.24
P/tB 9.24
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.43
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0
BVpS0.5
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -144.77%
ROE -189.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-265.83%
ROA(5y)-179.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.6
Quick Ratio 4.6
Altman-Z 0.23
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.86%
EPS Next Y24.9%
EPS Next 2Y10.31%
EPS Next 3Y9.12%
EPS Next 5Y12.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.05%
EBIT Next 3Y-44.37%
EBIT Next 5Y-5.41%
FCF growth 1Y26.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.99%
OCF growth 3YN/A
OCF growth 5YN/A

ANNOVIS BIO / ANVS FAQ

Can you provide the ChartMill fundamental rating for ANNOVIS BIO?

ChartMill assigns a fundamental rating of 2 / 10 to ANVS.


Can you provide the valuation status for ANNOVIS BIO?

ChartMill assigns a valuation rating of 0 / 10 to ANNOVIS BIO (ANVS). This can be considered as Overvalued.


What is the profitability of ANVS stock?

ANNOVIS BIO (ANVS) has a profitability rating of 0 / 10.


What is the financial health of ANNOVIS BIO (ANVS) stock?

The financial health rating of ANNOVIS BIO (ANVS) is 6 / 10.